Adimab Strikes its First Technology Transfer Deals with GSK and Biogen Idec
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 8 (Table of Contents)
Published: 8 Aug-2013
DOI: 10.3833/pdr.v2013.i8.1970 ISSN: 1756-7874
Section: Technology Access
Fulltext:
Abstract
GlaxoSmithKline has become the first pharmaceutical company to take Adimab’s antibody discovery platform in-house as part of a deal that provides the company with a broad, non-exclusive licence to use the technology to discover and optimise antibody therapeutics of all formats...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS